Compare EZPW & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZPW | TBPH |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 993.7M |
| IPO Year | 1991 | N/A |
| Metric | EZPW | TBPH |
|---|---|---|
| Price | $21.08 | $18.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.00 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 1.3M | 516.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.89 | N/A |
| EPS | ★ 1.42 | 0.58 |
| Revenue | ★ $1,274,280,000.00 | $80,327,000.00 |
| Revenue This Year | $11.91 | $70.78 |
| Revenue Next Year | $7.78 | N/A |
| P/E Ratio | ★ $14.83 | $31.31 |
| Revenue Growth | 9.70 | ★ 27.12 |
| 52 Week Low | $11.56 | $7.90 |
| 52 Week High | $21.49 | $20.33 |
| Indicator | EZPW | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 78.89 | 54.58 |
| Support Level | $19.86 | $17.25 |
| Resistance Level | $21.49 | $20.32 |
| Average True Range (ATR) | 0.56 | 0.73 |
| MACD | 0.20 | -0.28 |
| Stochastic Oscillator | 88.72 | 30.62 |
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buys and sells second-hand goods. The operating segments of the company are U.S. Pawn, Latin America Pawn, and Other Investments. The U.S. Pawn segment includes all pawn activities in the United States. The Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales, which are mainly collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).